Akkermansia muciniphila improves gastric cancer treatment by modulating the immune microenvironment

References

• Thrift AP, El-Serag HB. Burden of gastric cancer. Clin. Gastroenterol Hepatol. 18(3), 534–542 (2020).
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim. Biophys. Acta Rev. Cancer 1876(2), 188615 (2021).
   PubMed Web of Science ®Google Scholar
• Smyth E, Knodler M, Giraut A et al. VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study. Front. Oncol. 9, 1320 (2019).
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Fuchs CS et al. KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 15(9), 943–952 (2019).
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294), 27–40 (2021).
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398(10302), 759–771 (2021).
   PubMed Web of Science ®Google Scholar
• Wang F, Wei XL, Wang FH et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann. Oncol. 30(9), 1479–1486 (2019).
   PubMed Web of Science ®Google Scholar
• Jin X, Liu Z, Yang D, Yin K, Chang X. Recent progress and future perspectives of immunotherapy in advanced gastric cancer. Front. Immunol. 13, 948647 (2022).
   PubMed Web of Science ®Google Scholar
• Meng C, Bai C, Brown TD, Hood LE, Tian Q. Human gut microbiota and gastrointestinal cancer. Genomics Proteomics Bioinformatics 16(1), 33–49 (2018).
   PubMed Web of Science ®Google Scholar
• Correa P, Piazuelo MB. Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol. Hepatol. Rev. 7(1), 59–64 (2011).
   PubMedGoogle Scholar
• Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371), 91–97 (2018).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359(6382), 1366–1370 (2018).
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264), 1084–1089 (2015).
   PubMed Web of Science ®Google Scholar
• Das S, Suarez G, Beswick EJ, Sierra JC, Graham DY, Reyes VE. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J. Immunol. 176(5), 3000–3009 (2006).
   PubMed Web of Science ®Google Scholar
• Reunanen J, Kainulainen V, Huuskonen L et al. Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer. Appl. Environ. Microbiol. 81(11), 3655–3662 (2015).
   PubMed Web of Science ®Google Scholar
• Dao MC, Everard A, Aron-Wisnewsky J et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65(3), 426–436 (2016).
   PubMed Web of Science ®Google Scholar
• Shin NR, Lee JC, Lee HY et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63(5), 727–735 (2014).
   PubMed Web of Science ®Google Scholar
• Barcena C, Valdes-Mas R, Mayoral P et al. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. Nat. Med. 25(8), 1234–1242 (2019).
   PubMed Web of Science ®Google Scholar
• Bian X, Wu W, Yang L et al. Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice. Front. Microbiol. 10, 2259 (2019).
   PubMed Web of Science ®Google Scholar
• Zhai R, Xue X, Zhang L, Yang X, Zhao L, Zhang C. Strain-specific anti-inflammatory properties of two Akkermansia muciniphila strains on chronic colitis in mice. Front. Cell. Infect. Microbiol. 9, 239 (2019).
   PubMed Web of Science ®Google Scholar
• Ansaldo E, Slayden LC, Ching KL et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science 364(6446), 1179–1184 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu K, Zhang Q et al. Alpha fetoprotein promotes polarization of macrophages towards M2-like phenotype and inhibits macrophages to phagocytize hepatoma cells. Front. Immunol. 14, 1081572 (2023).
   PubMed Web of Science ®Google Scholar
• Wang L, Tang L, Feng Y et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8(+) T cells in mice. Gut 69(11), 1988–1997 (2020).
   PubMed Web of Science ®Google Scholar
• Luo ZW, Xia K, Liu YW et al. Extracellular vesicles from Akkermansia muciniphila elicit antitumor immunity against prostate cancer via modulation of CD8(+) T cells and macrophages. Int. J. Nanomedicine 16, 2949–2963 (2021).
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xia L, Liu Q et al. Induction of pro-inflammatory response via activated macrophage-mediated NF-κB and STAT3 pathways in gastric cancer cells. Cell. Physiol. Biochem. 47(4), 1399–1410 (2018).
   PubMedGoogle Scholar
• Jiang Y, Zhang M, Guo T, Yang C, Zhang C, Hao J. MicroRNA-21-5p promotes proliferation of gastric cancer cells through targeting SMAD7. Onco Targets Ther. 11, 4901–4911 (2018).
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang D, Yu K et al. CMPD1 inhibited human gastric cancer cell proliferation by inducing apoptosis and G2/M cell cycle arrest. Biol. Res. 51(1), 11 (2018).
   PubMedGoogle Scholar
• Yamaguchi T, Fushida S, Yamamoto Y et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer 19(4), 1052–1065 (2016).
   PubMed Web of Science ®Google Scholar
• Zhao Q, Cao L, Guan L et al. Immunotherapy for gastric cancer: dilemmas and prospect. Brief. Funct. Genomics 18(2), 107–112 (2019).
   PubMed Web of Science ®Google Scholar
• Hogner A, Moehler M. Immunotherapy in gastric cancer. Curr. Oncol. 29(3), 1559–1574 (2022).
   PubMed Web of Science ®Google Scholar
• Xu R, Wu J, Zhang X et al. Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1/PD-L1-dependent T cell immunization. Pharmacol. Res. 152, 104623 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang T, Li Q, Cheng L, Buch H, Zhang F. Akkermansia muciniphila is a promising probiotic. Microb. Biotechnol. 12(6), 1109–1125 (2019).
   PubMed Web of Science ®Google Scholar
• Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat. Rev. Gastroenterol. Hepatol. 19(10), 625–637 (2022).
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371), 97–103 (2018).
   PubMed Web of Science ®Google Scholar
• Li T, Lin X, Shen B et al. Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6(+) natural killer T cells. Front. Immunol. 13, 1047570 (2022).
   PubMed Web of Science ®Google Scholar
• Jin Y, Dong H, Xia L et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in chinese patients with NSCLC. J. Thorac. Oncol. 14(8), 1378–1389 (2019).
   PubMed Web of Science ®Google Scholar
• Shi L, Sheng J, Chen G et al. Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance. J. Immunother. Cancer 8(2), e000973 (2020).
   PubMed Web of Science ®Google Scholar
• Zhuo Q, Yu B, Zhou J et al. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci. Rep. 9(1), 20128 (2019).
   PubMedGoogle Scholar
• Riehl TE, Alvarado D, Ee X et al. Lactobacillus rhamnosus GG protects the intestinal epithelium from radiation injury through release of lipoteichoic acid, macrophage activation and the migration of mesenchymal stem cells. Gut 68(6), 1003–1013 (2019).
   PubMed Web of Science ®Google Scholar
• Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv. Drug Deliv. Rev. 114, 206–221 (2017).
   PubMed Web of Science ®Google Scholar
• Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18(5), 349–355 (2008).
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11(10), 889–896 (2010).
   PubMed Web of Science ®Google Scholar
• Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur. J. Pharmacol. 877, 173090 (2020).
   PubMed Web of Science ®Google Scholar
• Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv. Drug Deliv. Rev. 99(Pt B), 180–185 (2016).
   PubMed Web of Science ®Google Scholar
• Fan L, Xu C, Ge Q et al. A. muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like TAMs. Cancer Immunol. Res. 9(10), 1111–1124 (2021).
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu Y, Zheng C et al. Acetyltransferase from Akkermansia muciniphila blunts colorectal tumourigenesis by reprogramming tumour microenvironment. Gut 72(7), 1308–1318 (2023).
   PubMed Web of Science ®Google Scholar
• Plovier H, Everard A, Druart C et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23(1), 107–113 (2017).
   PubMed Web of Science ®Google Scholar
• Depommier C, Everard A, Druart C et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat. Med. 25(7), 1096–1103 (2019).
   PubMed Web of Science ®Google Scholar
• Zhu Z, Cai J, Hou W et al. Microbiome and spatially resolved metabolomics analysis reveal the anticancer role of gut Akkermansia muciniphila by crosstalk with intratumoral microbiota and reprogramming tumoral metabolism in mice. Gut Microbes 15(1), 2166700 (2023).
   PubMed Web of Science ®Google Scholar